Literature DB >> 16832089

CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.

B van de Langerijt1, J M Gijtenbeek, H P M de Reus, F C G J Sweep, A Geurts-Moespot, J C M Hendriks, A C Kappelle, M M Verbeek.   

Abstract

OBJECTIVE: To investigate the diagnostic value of transforming growth factor beta(1) (TGFbeta(1)), vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) in CSF for leptomeningeal metastasis (LM).
METHODS: The authors measured concentrations of biomarkers by ELISA in matched samples of CSF and serum, collected from 132 patients with a solid malignancy with LM (n = 19) and without LM (n = 54) and patients with viral (n = 16) and bacterial (n = 16) meningitis and a variety of nonmalignant, noninfectious neurologic disorders (n = 27). Indexes of the biomarkers (CSF/serum value relative to CSF/serum albumin ratios) were calculated to correct for the serum contribution to the CSF marker concentration.
RESULTS: CSF VEGF concentration was significantly higher in LM than in all other groups. VEGF indexes were also higher, although not significant. In contrast, the tPA index was significantly decreased in LM compared with all other groups. The combination of the VEGF and tPA indexes resulted in a sensitivity of 100% for LM and a specificity of 73% for the patient group with a primary tumor but without LM.
CONCLUSION: Patients with leptomeningeal metastasis have high vascular endothelial growth factor (VEGF) indexes and low tissue-type plasminogen activator (tPA) indexes. As cytologic examination of CSF lacks 100% sensitivity for the diagnosis of leptomeningeal metastasis (LM), the combination VEGF and tPA index analysis may be of additional value in the diagnostic workup of patients suspected of having LM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832089     DOI: 10.1212/01.wnl.0000223348.42106.97

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Leptomeningeal metastases.

Authors:  Jordi Bruna; Marta Simó; Roser Velasco
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 2.  Novel methods to diagnose leptomeningeal metastases in breast cancer.

Authors:  Lindsay Angus; John W M Martens; Martin J van den Bent; Peter A E Sillevis Smitt; Stefan Sleijfer; Agnes Jager
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

3.  Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells.

Authors:  Monika A Davare; Sangeet Lal; Jennifer L Peckham; Suresh I Prajapati; Sakir H Gultekin; Brian P Rubin; Charles Keller
Journal:  Biochem Biophys Res Commun       Date:  2014-06-10       Impact factor: 3.575

4.  Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis.

Authors:  Anne Constanze Regierer; Andrea Stroux; Dagmar Kühnhardt; Annette Dieing; Silvia Lehenbauer-Dehm; Bernd Flath; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2008-04-15       Impact factor: 2.860

Review 5.  Neuro-ophthalmologic complications of neoplastic leptomeningeal disease.

Authors:  Gabriella Szatmáry
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

6.  CSF CA 15-3 in breast cancer-related leptomeningeal metastases.

Authors:  Emilie Le Rhun; Andrew Kramar; Sophie Salingue; Marie Girot; Isabelle Rodrigues; Audrey Mailliez; Fahed Zairi; Edgar Bakhache; Yves Marie Robin; Sophie Taillibert; François Dubois; Jacques Bonneterre; Marc C Chamberlain
Journal:  J Neurooncol       Date:  2014-01-28       Impact factor: 4.130

7.  Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.

Authors:  Morris D Groves; Kenneth R Hess; Vinay K Puduvalli; Howard Colman; Charles A Conrad; Mark R Gilbert; Jeffrey Weinberg; Massimo Cristofanilli; W K Alfred Yung; Ta-Jen Liu
Journal:  J Neurooncol       Date:  2009-03-07       Impact factor: 4.130

8.  Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors.

Authors:  Lakshmi Nayak; Martin Fleisher; Rita Gonzalez-Espinoza; Oscar Lin; Katherine Panageas; Anne Reiner; Chhui-Mei Liu; Lisa M Deangelis; Antonio Omuro
Journal:  Neurology       Date:  2013-04-03       Impact factor: 9.910

9.  Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.

Authors:  Jing Liu; Bo Jin; Hang Su; Xiujuan Qu; Yunpeng Liu
Journal:  BMC Cancer       Date:  2019-07-17       Impact factor: 4.430

10.  Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2013-05-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.